Damora Therapeutics Inc DMRA

$21.96 +0.70 (3.29%)

Valuation

Market cap
1,302,012,000
Revenue TTM
$0
Net income TTM
$-209,840,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
286,000
Avg volume
572,710
Day's range
$20.23 – $22.27
Shares out
61,736,000
Stochastic %K
86%
Beta
1.43
Analysts
Strong Sell
Price target
$46.89

Price

Company profile

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the...

Show more

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
781 281 9020
Website
https://www.damoratx.com
Address
Building 23, Suite 105 221 Crescent Street, Waltham, United States

Latest news

Stocktwits

NotHopeJustFacts Oct 21, 2:10 PM
$DMRA can someone remind me why did i buy this trash (i bought it under Galecto) cause on my side they look as heavy bags... LOL
1 replies
S4T4N1ST Oct 1, 10:03 PM
$DMRA ENTRY PRICE 19.11
0 replies
CEOBuysDisclosures Sep 28, 1:05 PM
$DMRA CEO purchased 12,500 shares at $20.23 for a total of $252,875. Jarrett Jennifer now owns 512,500 shares. https://ceo-buys.com
0 replies
FilingTracker Sep 28, 11:01 AM
$DMRA President/CEO purchase: https://filingtracker.ai/filing/1671311/0001193125-26-403355?doc=ownership.xml
0 replies
KryptonResearch14 Sep 27, 8:28 AM
$DMRA Guggenheim went Street-high on a biotech with no clinical data: raised its target to 60 from 40 on Friday, Buy rating, implying about 196% upside off the 20.27 prior close (Benzinga, via Watch List News). Jefferies' 50 was the prior high. The stock needed the headline. Down 32% in a month and about 40% below its 34.89 52-week high. Friday volume ran 132% above the prior session's on the note. The drug: DMR-001, a once-monthly subcutaneous antibody against mutCALR for myeloproliferative neoplasms, a 5B-plus market (Seeking Alpha). It is in Phase 1/1b. Incyte's mutCALR competitor is further along. The cushion: about 540.5M in cash, runway into the second half of 2029. Guggenheim is pricing in a franchise with no human efficacy readout yet.
0 replies
notreload_ai Sep 25, 12:35 PM
Guggenheim raises $DMRA to $60 from $40, keeps Buy, and names it a Best Idea on a larger myelofibrosis outlook. https://notreload.xyz/xy/guggenheim-lifts-damora-target-to-60-best-idea/
0 replies
justiceforb_85 Sep 24, 8:08 PM
$DMRA nice to see the ticker name finally updated!
0 replies
justiceforb_85 Sep 24, 1:21 AM
$DMRA company with strong cash position with DMR-001 likely to be an improved version of INCA033989 addressing non-type 1 MPNs, larger market opportunity.
0 replies